Nicolas Ciattoni, Clinical Oncology Specialist at Claritymed shared a post on LinkedIn:
“Towards High-Performance Serum Biomarker Screening for Pancreatic Cancer ?
I find myself so surprised that this publication has not received the level of attention it deserves in PDAC expert circles.
Integrating the new markers ANPEP and PIGR with CA19-9 and THBS2 creates a 4-biomarker panel achieving 87.5% sensitivity for Stage I/II. This performance matches advanced imaging like 3T DWI-MRI, while the slightly more accurate EUS remains invasive and operator-dependent.
Crucially, the panel performance should be assessed more precisely between Stage 1A (tumor < 2 cm), where survival reaches 84%, compared to only 44% at Stage 1B (I personally consider PDAC as metastatic from 2cms in most configurations, reminding SCLC).
Would this panel outperform MCED tests and other complex ctDNA NGS-based assays?
This non-invasive blood test opens perspectives for reliable intervention at the earliest possible stage, before the disease progresses to a poor prognosis.
Reference: Brianna M Krusen et al. Clin Cancer Res. 2026.”
Title: Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric immunoglobin receptor (PIGR)
Authors: Brianna M. Krusen, Phyllis A. Gimotty, Greg Donahue, Jacob E. Till, Melinda Yin, Erin E. Carlson, William R. Bamlet, Erica L. Carpenter, Shounak Majumder, Ann L. Oberg, Kenneth S. Zaret
Read The Full Article
Other articles about Pancreatic Cancer on OncoDaily.